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Introduction 
The extensive use of mammography for screening has resulted in the recognition of 
increasing numbers of malignant or malignancy-suspicious breast tumors in an early stage. 
Consequently, the ratio of non-palpable lesions has increased among early stage breast 
tumors; these lesions are detected during routine mammographic screening first
1
. In parallel 
with the extensive use of mammographic screening, the surgical treatment has changed as 
well: conservative breast surgery (quadrantectomy, lumpectomy, excision of the tumor) has 
replaced the earlier radical breast surgery, and axillary lymph node dissection (ALND) has 
likewise been replaced by sentinel lymph node biopsy (SLNB), which is currently the 
established method with which to assign the axillary lymph node status in early breast 
cancers.
2,3 
 
Basically, there are two methods used to localize non-palpable breast tumors. The 
method of guidewire localization (GWL) described by Kopans in 1980 has been used for 
decades in the preoperative localization of non-palpable breast lesions
4
. The radioguided 
occult lesion localization (ROLL) method was developed by Luini and colleagues in the 
Institute of Oncology in Milan and is used since 1996
5
. This method has become a standard 
marking procedure; however, GWL is still used by several Institutions.  
For a century, ALND has been an essential component of the surgical treatment of 
invasive breast cancer. Axillary node status is one of the most important prognostic indicators 
in breast cancer, and of particular value in the choice of adjuvant therapy.
6,7
 SLNB has been 
developed as a minimally invasive diagnostic procedure for the accurate preoperative staging 
of the axilla and ALND could be avoided if the patients do not have metastases in the Sentinel 
Lymph Nodes (SLNs). The technique was first used by Morton and colleagues with blue dye 
8,9
 and later by van der Veen and colleagues 
10
 with lymphoscintigraphy in the treatment of 
patients with melanoma. Similarly, this method can be applied in the treatment of breast 
cancers in early stage. If the SLN can be accurately identified, and the histological 
examination reveals no metastasis in the SLNs, the other nodes (non-SLNs - NSLN) in the 
axilla are unlikely to contain metastases and the unnecessary ALND can be avoided.
11
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Current practice guidelines recommended the ALND for breast cancer patients whose 
SLN contains metastatic cancer.
12,13,14
 It is important to know that 40% to 70% of patients 
with positive SLNs are found to have no other NSLN metastases.
15,16
 Therefore, these patients 
undergo unnecessary ALND without therapeutic benefit or additional information for the 
staging. Furthermore, completion ALND is associated with substantial morbidity affecting up 
to 39% of patients, with a nearly three-fold increased risk of lymphedema or regional sensory 
loss.
17,18
 Based on these, it would be important to create a predictive model detecting patients 
who might benefit from ALND in case of SLN metastasis of the invasive breast tumor and 
this would provide additional information regarding tumor staging and would have additional 
therapeutic benefit as well.  
In addition to early stage invasive breast tumors, the importance of in situ ductal cancers 
has increased. Before the widespread introduction of mammographic screening, only 1-2% of 
the recognized breast cancers comprised DCIS (Ductal Cancer in situ of the breast), but at 
present, the rate of detection by mammographic screening of non-palpable breast cancers is 
approximately 20%.
19,20 
DCIS is defined as a non-invasive breast cancer, and is widely 
considered not to give metastases to the lymph nodes, so that ALND would comprise 
overtreatment.
20,21 
Nonetheless, a number of studies have reported the detection of metastases 
in SLNs in patients with DCIS, though with a very low incidence. 
22,23,24,25,26,27,28,29,30 
In situ 
breast cancers require a novel approach in planning the surgical treatment as well, which 
suggests that SLNB may be omitted in such cases. 
The purpose of our study 
I. Comparing the methods of localization of non-palpable breast tumors (ROLL, GWL) 
(Study 1). 
II. Finding factors influencing NSLN metastasis, creating predictive nomograms, and 
comparing them with international nomograms (Study 2). 
III. Simplifying option of the surgical treatment of in situ breast tumors (Study 3). 
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Patients and methods 
Our studies were conducted in the Department of Surgery, Faculty of Medicine, 
University of Szeged. 
Patients having a surgery using the GWL method (N = 69 patients) between January 1, 
1997 and December 31, 2001 and the ROLL method (N = 321 patients) between January 1, 
2002 and December 31, 2008 for having non-palpable unilateral malignant breast tumor and 
who had primary breast conservative surgery (BCS) were enrolled in Study 1. 
Patients having a surgery using the ROLL method (N = 824) for having early stage 
unilateral malignant tumor between January 1, 2004 and December 31, 2011 who had primary 
breast tumor removal (BCS or mastectomy) and SLNB simultaneously were enrolled in 
Study 2. 
Patients having a surgery using the ROLL method (N = 112) between January 1, 2002 
and December 31, 2011 in case of whom the final histological examination confirmed 
unilateral in situ breast tumor were enrolled in Study 3. 
1. WGL method 
69 patients with a non-palpable malignant breast tumor were operated on in our institute 
following GWL between January 1, 1997 and December 31, 2001. During the intervention, a 
hook wire was introduced by the radiologist under radiographic or ultrasound guidance 
immediately before surgery. Direction of hook-wire insertion: for lesions in the upper 
quadrant/central region, preference is given to the cranio-caudal direction; for lesions in the 
lower quadrant, we prefer the lateral approach (these directions ensure the shortest way and at 
the same time are the most appropriate for the surgical incision). Exact positioning of the 
hook-wire (<5 mm) is important. The position of the wire was controlled by mammography. 
During the operation, the excision involved the tumor that was marked by a wire. The level of 
excision was the pectoral fascia. The excised specimen was marked with orientation stitches, 
and then specimen mammographic tests were performed.
4
 Depending on the preoperative or 
final histological results, the procedure was supplemented with ALND because at that time, 
we did not use of SLNB. In the event of positive surgical margins, a supplementary operation 
(re-resection or mastectomy) was performed.  
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2. ROLL method  
321 patients with non-palpable malignant breast tumor were operated on in our institute 
with the application of the ROLL method between January 1, 2002 and December 31, 2008. 
The ROLL technique and double marking SLNB were used simultaneously.
31
 One day before 
the operation, 0.4 mL 
99m
Tc-labeled human colloid albumin was injected into the tumor under 
radiographic or ultrasound guidance. 4 hours later, it was followed by a lymphoscintigraphic 
examination, and the projections of the SLNs on the skin were marked from two sides (SLN 
mapping). On the following day, 10 minutes before the operation, a second marker substance 
for the SLN, Patent Blue dye (2 mL) was injected into the subareolar region of the breast. 
During the operation, radiocolloid activity peak was identified with a gamma probe and the 
tumor was removed and the preoperative findings were also taken into account. The level of 
excision was the pectoral fascia. The excised specimen was marked with orientation stitches 
and controlled by specimen mammography. In patients with positive surgical margins, a 
second operation (re-resection or mastectomy) was performed. If metastases were detected in 
the SLNs, ALND was performed. 
Radiologists recorded the time (minutes) required to localize the lesion with wire or 
isotope substance. Surgeons recorded the time (minutes) required for excisions (without 
axillary surgery). 
3. Histological methods 
Pathological examination of the removed breast tissue 
During the pathological examination, the resection surface of the removed breast tissue was 
stained with various substances: anterior black (Indian ink), posterior blue (Alcian Blue) and 
superior red (Cadmium Red). The mass and the mediolateral, superoinferior and 
anteroposterior sizes of the removed tissue were measured. During the operation, a cylinder-
form breast specimen was removed, and specimen volume could be calculated. After that, 
sections were cut, and the size of the tumor and its distance from the resection surface of the 
tissue were measured. During the procedure, at least 11 blocks were performed with the first 
superoinferior section being the macroblock. In this way, we were able to measure the size of 
the tumor and its distance from the anterior, posterior, superior and inferior resection surfaces. 
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The second block (medial) included the medial part of the tumor from the macroblock to the 
medial resection margin. With the help of this block, we were able to measure the distance 
between the tumor and the medial resection margin. The third block (lateral) included the 
lateral part of the tumor from the macroblock to the lateral resection margin providing the 
measurement of the distance between the tumor and the lateral resection margin. The shaves 
involved blocks 4–11. Besides traditional sections, we made 8 extra sections thus dividing the 
external surface of the removed tissue into 8 parts (superior, superomedial, superolateral, 
medial, lateral, inferomedial, inferolateral and inferior). By preparing these sections, our 
investigation of the resection margins became more precise. 
32
 During the examination were 
investigated the volume of removed specimen, the histological type of the tumor, the size of 
the tumor (T stage), the presence of in situ breast cancer around the invasive component, 
multifocality, the presence of lymphovascular invasion (LVI), histological grade, estrogen 
(ER) and progesterone receptor (PR) status and Human Epidermal Growth Factor Receptor-2 
(HER-2) gene expression. The three diameters of the removed specimen (anteroposterior, 
mediolateral, superoinferior) were measured by pathologists, and the volume of the specimen 
was calculated with using an equation applied in case of an elliptical tissue cylinder. 
Pathologists considered multifocality where two or more invasive cancer foci could be found 
in the same quadrant of the breast and where there was no contact between the invasive 
focuses. Extensive in situ breast cancer around the invasive focus was defined in cases where 
the proportion of intraductal component was at least 25%, and intraductal focuses were 
present in the adjacent breast tissue as well. Microinvasive breast carcinoma (DCIS with 
microinvasion – DCISM) was defined if the extension of cancer cells beyond the basement 
membrane into the adjacent tissues is with no single focus larger than 1 mm in greatest 
dimension. For hormonal receptor status, 10% staining of cells by Immunohistochemical 
staining (IHC) was considered positive. 
Pathological examination of the removed SLNs 
SLNs were first examined using routine hematoxylin-eosin (HE) staining. If the 
metastasis can be confirmed by HE staining, additional processing was not performed. If this 
examination did not confirm metastasis, SLNs were evaluated in serial sections at intervals of 
250 μm by means of HE. IHC staining was performed if the SLN was suspicious for 
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metastasis but HE was not able to identify the tumor cells accurately. Negative SLNs did not 
undergo IHC testing. The maximum dimension of the metastasis in each SLNs was measured 
since 2008, previously were described just the types of metastases (isolated tumor cells (ITC), 
micrometastasis or macrometastasis). Macrometastasis was defined if the SLN contains tumor 
metastasis in higher diameter than 2 mm. Micrometastasis was defined if the measure of SLN 
metastasis was between 0.2 and 2 mm. ITC metastasis in the SLN was defined if the measure 
of the metastasis was smaller than 0.2 mm. All SLNs were examined for extranodal 
extension. NSLNs from the ALND specimen were analyzed by routine HE staining only.  
When comparing the GWL and the ROLL methods, we have taken into consideration 
the preoperative localization time, the operating time, the age of the patients, the pathological 
size of the tumor, the volume of the removed specimen, the ratio of the tumor size and the 
removed specimen volume, the number of positive surgical margins, the subsequent 
reoperations (reexcision or mastectomy) and the postoperative complications (wound 
infections). Furthermore, we investigated other factors, such as the presence of an extensive in 
situ breast carcinoma around the invasive cancer and the presence of multifocal tumors, as 
they could have an impact on the frequency of positive resection margins.  
During the examination of the predictive factors of NSLN metastasis, the following 
variables were evaluated: tumor size, palpability, histological type of the tumor, grade of 
differentiation of the tumor, the presence of LVI, ER status, PR status, HER-2 status, number 
of removed SLNs, number of metastatic SLNs, the size of the metastasis in the SLNs, and 
presence of extranodal invasion. 
During the evaluation of in situ tumors, the histological type, size, and grade of 
differentiation of the tumor, and the histological finding of the removed SLNs were examined.  
4. Statistical analysis 
For the comparison of continuous variables, t-test and one-way analysis of variance were 
used, as well as the Mann-Whitney in cases of non-normality. The normal distribution of 
samples was tested by using the Kolmogorov-Smirnov test. Categorical data were analyzed 
by using chi-square and Fisher’s exact test. Multivariate analysis was performed by using 
logistic regression. SPSS version 20.0 (© 2012 SPSS Inc.) was used for statistical analysis. 
Significance was considered at p<0.05 
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Results 
Study 1: Comparing the ROLL and the GWL methods 
The final histological examination revealed 69 malignant lesions in the GWL group, and 
321 malignant lesions in the ROLL group. Table 1 presents the histological results of the 
removed malignant breast lesions (Table 1). 
Ultrasonographic guidance localization was performed in 58 cases using GWL method 
and in 277 cases using ROLL method. Radiographic guidance localization was performed in 
11 cases using the GWL method and in 44 cases using the ROLL method. The localization 
time was significantly shorter in the ROLL group both with ultrasonographic guidance 
(5.7±1.4 min vs. 21.6±2.4 min, p=0.05) and with radiographic guidance (21.8±3.1 min vs. 
41.6±3.8 min, p=0.021). It must be taken into consideration, however, that every time the 
GWL method was used, patients underwent mammography to verify the correct localization 
of the guidewire, which of course increased the localization time in all GWL cases. There was 
no significant difference in the operating time requirements (30.2±4.6 min vs. 30.7±4.7 min). 
The mean age of the patients was similar in both groups (59 yrs vs. 57.7 yrs). The removed 
breast specimen volume did not differ significantly between the GWL (89.5±116.3 cm3) and 
the ROLL group (104.1±78.6 cm3). The pathological tumor size and ratio of tumor size and 
Type of specimen GWL (N=69) ROLL (N=321) 
LCIS 
DCIS 
Papillary in situ breast cancer 
– 
5 (7.3%) 
– 
3 (0.9%) 
53 (16.5%) 
3 (0.9%) 
DCISM 4 (5.8%) 4 (1.3%) 
IDC 54 (78.3%) 218 (67.9%) 
ILC 3 (4.3%) 20 (6.3%) 
Mucinous carcinoma 
Tubular carcinoma 
Papillary carcinoma 
Phylloid carcinoma 
Mixed carcinoma 
Medullary carcinoma 
2 (2.9%) 
– 
– 
– 
– 
1 (1.4%) 
1 (0.3%) 
7 (2.2%) 
2 (0.6%) 
1 (0.3%) 
9 (2.8%) 
– 
Table 1. Pathological features of the GWL and ROLL groups
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removed specimen did not show any significant difference between the GWL and the ROLL 
groups. The final pathological examination revealed 16 patients (23.2%) with a positive 
resection margin in the GWL group (n=69). Reoperations were performed on 14 of these 
patients (20.3%); 5 patients (7.2%) underwent breast reexcision and 9 patients (13.1%) 
mastectomy, and 2 patients refused consent to mastectomy. Residual tumor tissue was found 
by the histological examination in 6 patients (8.7%). In the ROLL group (n=321), positive 
resection margins were detected by the final pathological examination in 47 of the cases 
(14.6%). Reoperations were performed on 46 of these patients (14.3%); 24 patients (7.5%) 
underwent breast reexcision, and 22 patients (6.8%) underwent mastectomy. One patient 
refused mastectomy. Residual tumor tissue was found by the histological examination in 25 
patients (7.8%). No significant difference was detected between the GWL and the ROLL 
groups in the frequency of positive resection margins. The incidence of postoperative 
complications (wound infections) did not differ significantly in the two groups (Table 2). 
 GWL (N=69) ROLL (N=321) p value 
Duration of localization (mean ±SD), min 
  Radiographic guidance 
  Ultrasound guidance 
 
41.6±3.8  
21.6±2.4 
 
21.8±3.1  
5.7±1.4 
 
0.021 
0.05 
Duration of surgical excision (mean ±SD), min  30.2±4.6 30.7±4.7 NS 
Mean age, yr 59 57.7 NS 
Removed breast specimen volume (mean ± SD), cm3 89.5±116.3 104.1±78.6 NS 
Pathological size of tumor (mean ± SD), mm 12.4±8.6 15.2±11.2 NS 
Size of the tumor (cm)/specimen volume (cm
3
) 0.0237±0.0258 0.0181±0.0179 NS 
Involved surgical margin(s), n (%) 16 (23.2%) 47 (14.6%) NS 
Residual tumor, n (%) 6 (8.7%) 25 (7.8%) NS 
Wound infections, n (%) 2 (2.9%) 3 (0.9%) NS 
Table 2. Comparison of various factors between GWL and ROLL in malignant breast tumors  
(NS-not significant)
 
 We have also taken further factors into consideration that influenced the frequency of 
positive resection margins. In the GWL group, 2 of the 69 patients (2.9%) had multifocal 
breast tumor, and another 4 patients (5.8%) had extensive in situ tumor components around 
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the invasive cancer. In the ROLL group 22 of the 321 patients (6.8%) had multifocal breast 
tumors, and 37 of the 321 patients (11.5%) had extensive in situ tumor components around 
the invasive cancer. The results of the histological analysis of the patients in the ROLL group 
indicated, that the size of the malignant lesion (p=0.021), the presence of a multifocal tumor 
(p=0.035), and the presence of an extensive in situ breast carcinoma around the invasive 
cancer (p=0.01) significantly increased the frequency of positive resection margins (Table 3). 
 ROLL N=321 (100%) p value 
 Involved surgical margins Clear margins  
Patients, n (%) 47 (14.6%) 274 (85.4%)  
Mean age, yr 55.6 58.1 NS 
Specimen volume (mean ± SD), cm3 119.9±104.7 111.7±73.4 NS 
Tumor size  (mean ± SD), mm 22.8±19.5 13.9±8.5 0.021 
Extensive DCIS present around the 
invasive cancer, n (%) 
12 (25.5%) 25 (9.1%) 0.01 
Multifocal lesion, n (%) 8 (17%) 14 (5.1%) 0.035 
Table 3. Investigated features and surgical margin status in the ROLL group (NS-not significant) 
In the GWL group the size of the tumors (p=0.05), the presence of an extensive in situ 
breast carcinoma around the invasive cancer (p=0.05) and the volume of the removed breast 
specimen (p=0.002) influenced the occurrence of unclear margins considerably. The 
frequency of reexcision was also higher for smaller specimens (Table 4). 
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 GWL n=69 (100%) p value 
 Involved surgical margins Clear margins  
Patients, n (%) 16 (23.2%) 53 (76.8%)  
Mean age, yr 58.4 60.6 NS 
Specimen volume (mean ± SD), cm3 66.4±40.3 96±127.1 0.002 
Tumor size (mean ± SD), mm 17±11.6 11.2±7.4 0.05 
Extensive DCIS present around the invasive 
cancer, n (%) 
2 (12.5%) 2 (3.8%) 0.05 
Multifocal lesion, n (%) 1 (6.3%) 1 (1.9%) NS 
Table 4. Investigated features and surgical margin status in the GWL group (NS-not significant) 
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Study 2: Lymph node prognostic factors 
Between January 1, 2004 and December 31, 2011, the final histological examination 
confirmed invasive carcinoma in case of 855 patients having a surgery using the ROLL 
method; in case of these patients, SLNB was also planned simultaneously. In 824 cases, 
marking of the SLN was successful (824/855 – 96.3%) using dual marking procedure, and 
successful SLNB was performed in all 824 cases. Based on the histological findings, the 
majority of the tumors was invasive ductal carcinoma (IDC) (79.1%), followed by invasive 
lobular carcinoma (ILC) (9.9%) and mixed type carcinoma (4.4%) (Table 5, Figure 1). 
Histology Number of cases (N) %  
IDC 652 79.1 
ILC 80 9.7 
Mixed carcinoma 36 4.4 
Other less common carcinomas 56 6.8 
Tubular carcinoma 
Papillary carconoma 
Medullar carcinoma 
Mucinous carcinoma 
Aplastic carcinoma 
Undifferentiated carcinoma 
Carcinosarcoma 
Cribriform carcinoma 
Neuroendocrine carcinoma 
Metaplastic carcinoma 
Micropapillar carcinoma 
Epithelial carcinoma 
16 
9 
8 
14 
1 
1 
1 
1 
1 
2 
1 
1 
2 
1.1 
1 
1.7 
0.1 
0.1 
0.1 
0.2 
0.1 
0.2 
0.1 
0.1 
Table 5. Histological findings of invasive breasts tumors 
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Figure 1. Histological types of breast tumors 
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A total of 1328 SLNs were removed from 824 patients, which means an average of 1.6 
lymph nodes per patient. SLN metastasis was not confirmed by histology in 553 cases 
(553/824 – 67.1%), but in 271 cases (271/824 – 32.9%), SLN metastases were found. In 205 
patients, complementary ALND was performed. In the other 66 cases, ALND was not 
performed based on the decision of the oncoteam regarding the patient’s age and compliance, 
the size of the metastasis (ITC or micrometastasis), and in two cases, patients did not agree to 
perform the complementary surgery. 
Then we studied the connection between primary tumor characteristics and NSLN 
metastasis in case of SLN positivity first with one-way analysis of variance in patients having 
complementary ALND (205 patients). In 70 patients (70/205 34.1%), additional metastasis 
was confirmed in the axillary lymph nodes by histological examination (Figure 2).  
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Figure 2. Histological finding of lymph node biopsies 
Average age of the patients was significantly different between the NSLN negative and 
NSLN metastatic groups (55±11.1 years vs. 58.8±10.1 years, p=0.034). 75.6% (102/135) of 
NSLN negative patients had palpable tumor, while this ratio was 84.3% (59/70) in patients 
with NSLN metastasis, the difference was not significant (p=0.209). The presence of 
multifocal tumor did not influence the incidence of the metastasis in the NSLNs (NSLN 
negative: 11/135 – 8.1%, and NSLN positive 10/70 – 14.3%; p=0.224). The tumor size 
correlated with the incidence of the NSLN metastasis (NSLN negative: 18.8±8.1 mm vs. 
NSLN positive: 22.6±10.6 mm; p=0.019). Comparison was also made based on histological 
type. IDC was the most common (83.9%), followed by ILC (8.3%), and mixed type (lobular + 
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ductal) carcinoma (5.9%). The incidence of less common tumors (other histological tumors) 
was 2%. The histological types of the tumors did not influence the incidence of a NSLN 
metastasis (p=0.375). Studying the grade of histological differentiation revealed that the ratio 
of grade 1 tumors was 14.1% (19/135) in NSLN negative cases, and 8.6% (6/70) in NSLN 
positive patients. The incidence of NSLN metastasis was not different in grade 2 (NSLN 
negative: 64/135 - 47.4% vs. NSLN positive: 39/70 – 55.7%) or grade 3 tumors (NSLN 
negative: 52/135 – 38.5% vs. NSLN positive: 25/70 – 35.7%) either (p=0.397). The presence 
of LVI did not influence the incidence of additional NSLN metastasis (NSLN negative: 
36/135 26.7% vs. NSLN positive: 17/70 24.3%; p=0.74). Neither ER positivity (NSLN 
negative: 107/135 – 79.2% vs. NSLN positive: 51/70 – 72.9%; p=0.274), nor PR positivity 
(NSLN negative: 101/135 – 74.8% vs. NSLN positive: 46/70 – 65.7%; p=0.24), nor HER-2 
gene expression influenced the incidence of metastasis in the NSLN (NSLN negative: 24/135 
– 17.8% vs. NSLN positive: 13/70 – 18.6%; p=0.848) (Table 6). The sizes of the metastasis in 
the removed SLNs were significantly different between the NSLN negative and positive 
groups (NSLN negative: 5.1±4.1 mm vs. NSLN positive: 8.1±4.6 mm, p<0.0001), however, 
there were only 148 patients in the latter group regarding the fact that before 2008, the proper 
size of the SLN metastasis was not routinely measured, only the type of the metastasis was 
determined (ITC-, micro- or macrometastasis). These groups were examined as well, but this 
comparison could be made with all 205 patients again. We found that in case of 
macrometastasis, the incidence of NSLN metastasis was significantly increased (p=0.013). 
Extracapsular spreading of the metastasis in the SLN did not influence the incidence of NSLN 
metastases (NSLN negative: 18/135 – 13.3% vs. NSLN positive: 16/70 – 22.9% p=0.112). 
The number of removed SLNs (p=0.37) and that of the SLNs containing a tumor (p=0.395) 
did not increase the risk of additional NSLN metastasis (Table 6-7). 
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Tumor 
characteristics 
Patients with 
negative NSLN 
(N=135) 
% Patients with 
positive NSLN 
(N=70) 
% p value 
(univariate) 
p value 
(multivariate) 
Age (yr) 55.1±11.1  58.8±10.1  0.034 0.073 (1) 
0.057 (3) 
Histology 
   IDC 
   ILC 
   Mixed 
   Other 
 
117 
9 
6 
3 
 
86.7 
6.7 
4.4 
2.2 
 
55 
8 
6 
1 
 
78.6 
11.4 
8.6 
1.4 
0.375  
Palpability 
   0 (no) 
   1 (yes) 
 
33 
102 
 
24.4 
75.6 
 
11 
59 
 
15.7 
84.3 
0.209  
Multifocality 
   0 (no) 
   1 (yes) 
 
124 
11 
 
91.9 
8.1 
 
60 
10 
 
85.7 
14.3 
0.224  
Tumor size 
  (mean ± SD),     
   mm 
18.8±8.1  22.6±10.6  0.019 0.065 (1) 
0.041 (2) 
0.014 (3) 
0.009 (4) 
Grade 
   1 
   2 
   3 
 
19 
64 
52 
 
14.1 
47.4 
38.5 
 
6 
39 
25 
 
8.6 
55.7 
35.7 
0.397  
LVI 
   0 (no) 
   1 (yes) 
 
99 
36 
 
73.3 
26.7 
 
53 
17 
 
75.7 
24.3 
0.74  
ER 
   0 (no) 
   1 (yes) 
   Missing  
 
24 
107 
4 
 
17.8 
79.2 
3 
 
17 
51 
2 
 
24.3 
72.9 
2.8 
0.274  
PR 
   0 (no) 
   1 (yes) 
   Missing 
 
32  
101 
2 
 
23.7 
74.8 
1.5 
 
22 
46 
2 
 
31.4 
65.7 
2.9 
0.24  
HER2 
   0 (no) 
   1 (yes) 
   Missing 
 
109 
24 
2 
 
80.7 
17.8 
1.5 
 
54 
13 
3 
 
77.1 
18.6 
4.3 
0.848  
Table 6. Importance of tumor prognostic factors in case of NSLN metastasis 
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Tumor characteristics Patients 
with 
negative 
NSLN 
(N=135) 
% Patients 
with 
positive 
NSLN  
(N=70) 
% p value 
(univariate) 
p value 
(multivariate) 
Type of SLN 
metastasis 
   ITC 
   MIC 
   MAC 
 
 
1 
21 
113 
 
 
0.7 
15.6 
83.7 
 
 
0 
3 
67 
 
 
0 
4.3 
95.7 
0.013 0.047 (3) 
0.03 (4) 
Size of SLN     
   metastasis, 
   (mean ± SD) mm,      
   (N=148) 
5.1±4.1  8.1±4.6  <0.0001 0.002 (1) 
0.001 (2) 
Extracapsular 
invasion of SLN 
metastasis 
   0 (no) 
   1 (yes) 
 
 
 
117 
18 
 
 
 
86.7 
13.3 
 
 
 
54 
16 
 
 
 
77.1 
22.9 
0.112  
No. of removed SLNs 
   1 
   2 
   3 
   4 
   6 
 
63 
47 
20 
4 
1 
 
46.7 
34.8 
14.8 
3 
0.7 
 
42 
16 
10 
2 
0 
 
60 
22.9 
14.3 
2.8 
0 
0.37  
No. of positive SLNs  
   1 
   2 
   3 
   4 
 
109 
23 
2 
1 
 
80.8 
17 
1.5 
0.7 
 
53 
13 
3 
1 
 
75.7 
18.6 
4.3 
1.4 
0.395  
Table 7. Importance of SLN prognostic factors in case of NSLN metastasis 
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Factors confirmed to be significant with one-way analysis of variance are described in 
Figure 3. 
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Figure C Figure D 
Figure 3. Age (Figure A), tumor size (Figure B), and size of SLN metastasis (Figure C; N=148 cases), 
and type of the SLN metastasis (Figure D; N=205 cases) in the NSLN negative and positive groups, 
figures include mean + SD, significance values 
Then factors found to be significant with one-way analysis of variance were tested with 
logistic regression (age, tumor size, size, and type of the SLN metastasis). More studies were 
performed. In our first study (1), if the size of the SLN metastasis was known and all three 
variables were included, age (p=0.073) and tumor size (p=0.065) did not influence the 
incidence of NSLN metastasis significantly, but the size of the SLN metastasis was found to 
be significant (p=0.002). The second study (2) was performed omitting the age from logistic 
regression. In this case, tumor size (p=0.041) and the size of the SLN metastasis (p=0.001) 
significantly influenced the incidence of metastasis in NSLN. In the third study (3), if the 
exact size of the SLN metastasis was not known only the type of it (macro-, or 
micrometastasis) and all three variables were included, age was strictly not significant 
(p=0.057), but the tumor size (p=0.014) and the type of the SLN metastasis were significantly 
(p=0.047) influencing the incidence of NSLN metastasis. The fourth study (4) was performed 
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similarly to the second one, age was not included in the analysis, in this case, tumor size 
(p=0.009) and the size of the SLN metastasis (p=0.03) significantly influenced the incidence 
of metastasis in NSLN (Table 6-7). 
Based on our results, we tried to construct a model to predict the incidence of additional 
NSLN metastasis. The probability of the metastasis can be calculated by the following 
equitation if the size of the SLN metastasis is known in the first case: 
PNSLNmet= )416.4s*144.0t*038.0a*034.0(e1
1
 
in the second case:  
PNSLNmet= )562.2s*151.0t*042.0(e1
1
 
where: PNSLNmet – the probability of NSLN metastasis 
 a – age (year) 
 t – tumor size (mm) 
 s – size of the metastasis in the SLN (mm) 
If the size of the SLN metastasis is not known only the type of it, the following equitation can 
be used to calculate the probability of NSLN metastasis in the third case: 
PNSLNmet= )701.1m*283.1t*041.0a*028.0(e1
1
 
in the fourth case: 
PNSLNmet= )016.0m*405.1t*043.0(e1
1
 
where: PNSLNmet – the probability of NSLN metastasis 
 a – age (year) 
 t – tumor size (mm) 
 m – type of the metastasis in the SLN (mac=1, mic=2) 
  
 
- 24 - 
Evaluation of the specificity and sensitivity of the first model using the Receiver Operating 
Characteristic (ROC) curve showed that its predictive value – based on the AUC=0.735 (Area 
Under the Curve) value is considered to be moderate, while the predictive value of the second 
model using the ROC curve similarly was somewhat lower (AUC=0.717) than the first one 
(Figure 4). Analysis of the third and fourth models with the ROC curve showed low 
predictive values (AUC=0.66 and 0.638), it practically cannot be used to predict NSLN 
metastasis (Figure 5).  
 
 
 
 
Figure A 
 
 
 
 
Figure B 
Figure 4. Diagram presenting the reliability of the predictive models regarding specificity and 
sensitivity and predicted and actual incidence of NSLN metastases (ALND or ABD met); Figure A in 
case of the three-variable model (AUC=0.735), Figure B in case of the two-variable model 
(AUC=0.717) if the exact size of the SLN metastasis is known 
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Further examination of the first predictive nomogram revealed that in patients with 
lower risk for NSLN metastasis, the nomogram is relatively more accurate in predicting the 
NSLN metastasis. Using a cut-off value of 0.27 in case of the predictive curve, the predictive 
value of the model could be increased, a sensitivity of 62.5 % and a specificity of 75 % could 
be achieved, this is the most accurate range of the nomogram. We tried to improve sensitivity 
 
 
 
 
Figure A 
  
  
Figure B 
Figure 5. Diagram presenting the reliability of predictive values of the models regarding specificity 
and sensitivity and predicted and actual incidence of NSLN metastases (ALND or ABD met); Figure 
A in case of the three-variable model (AUC=0.66), Figure B in case of the two-variable model 
(AUC=0.638) if only the type of the SLN metastasis (macro-, or micrometastasis) is known 
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and specificity similarly in case of the other nomograms as well; the results are seen in  
Table 8. 
Nomogram AUC Cut off value Sensitivity 
(%) 
Specificity 
(%) 
1. Diagram 0.735 0.27 62.5 75 
2. Diagram 0.717 0.35 55.4 81.3 
3. Diagram 0.66 0.34 69.6 67 
4. Diagram 0.638 0.36 57.1 64.4 
Table 8. Most accurate predictive ranges of the nomograms 
In summary, in case of SLN positivity, the patient’s age, the tumor size, and the size 
(type) of the SLN metastasis influenced the NSLN metastasis according to the one-way 
analysis of variance. Multivariate analyses of cases where the size of the SLN metastasis is 
known showed that only the size of the SLN metastasis was strictly significant, age and tumor 
size showed only borderline significance. If the age was not included in the multivariate 
analysis, the tumor size and the size of the SLN metastasis were significant factors. If only the 
type of the SLN metastasis is known, multivariate analysis showed borderline significance in 
case of the age, but the tumor size and the type of the SLN metastasis were still significant, 
even if the age was not included in the analysis. The predictive value of the models is 
moderate if the size of the SLN metastasis is known, while it is poor if only the type of the 
SLN metastasis is known. In case of patients with lower risk for NSLN metastasis, the 
predictive value of the nomogram is relatively more accurate.  
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Study 3: Importance of SLNB in case of in situ breast carcinomas 
Between January 1, 2002 and December 31, 2011, patients having surgery using the 
ROLL method with a final histological examination confirming in situ breast tumor (N = 112 
patients) were enrolled in the study. The median age of the patients was 55.2 years (range 30–
78 years). 75 patients (75/112, 67%) underwent preoperative fine-needle aspiration cytology 
(FNAC) and 23 patients (23/112, 20.5%) underwent core-needle biopsy (CNB). Preoperative 
histological results were not available in 13 patients. FNAC was not informative (C1) in 28 of 
75 patients (28/75, 37.3%), 3 patients (3/75, 4%) had a benign breast disease (C2), 5 (5/75, 
6.7%) had atypical breast disease (C3), 19 (19/75, 25.3%) gave the suspicion of malignant 
disease (C4) and only in 20 (20/75, 26.7%) were malignant cells identified in the sample (C5). 
Of the 23 patients investigated by CNB, malignant breast cancer (pure DCIS) was identified 
in 17 (17/23 73.9%), invasive cancer in 2 (2/23, 8.7%), atypical breast disease in 2 (2/23 
8.7%) and benign breast disease in 2 (2/23, 8.7%) cases (Table 9).  
Results of FNAC N % 
No cells detected (C1) 28 25.0 
Benign disease (C2) 3 2.7 
Atypical disease (C3) 5 4.4 
Suspected malignancy (C4) 19 17.0 
Malignant cells (C5) 20 17.8 
Results of CNB     
Benign disease (B2) 2 1.8 
Atypical disease (B3) 2 1.8 
Malignant disease pure in situ cancer (B5a) 17 15.2 
Malignant disease in situ and invasive cancer (B5a+b) 2 1.8 
Excision 1 0.9 
Data not available  13 11.6 
Table 9. Results of preoperative histological diagnosis 
The final histological examination verified lobular in situ breast cancer (LCIS) in 4 of 
the 112 patients (4/112, 3.6%), pure DCIS in 96 (96/112, 85.7%), papillary in situ cancer in 3 
(3/112, 2.7%) and DCISM in 9 (9/112, 8%) patients (Table 10). 36 patients (36/112, 32.1%) 
had palpable tumor. DCIS breast cancers have a number of histological subtypes (solid, 
cribriform, papillary, micropapillary and comedo). The most important factors are the 
presence of comedo necrosis and the grade of the tumor cells. In 76 of the 108 pure DCIS 
patients (76/108, 70.4%), the tumor was of high grade (Grade III), in 11 (11/108, 10.2%) 
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cases, it was of intermediate grade (Grade II), and in 21 (21/108, 19.4%) cases, it was of low 
grade (Grade I). 
Histological type N % 
LCIS 4 3.6 
DCISM 9 8.0 
Pure DCIS 96 85.7 
Papillary in situ cancer 3 2.7 
Table 10. Final pathologic diagnosis 
Simultaneous SLNB was planned in 108 of the 112 patients (108/112, 96.4%), while 4 
(4/112 3.6%) patients underwent only wide excision. In 8 of 108 patients (8/108, 7.4%), SLNs 
were not identified; axillary sampling or ALND was performed to remove the axillary lymph 
nodes at level I-II. 100 patients underwent successful SLNB (100/108, 92.6%). In 95 cases, 
SLNs were evaluated in serial sections at intervals of 250 µm with using HE, while in 5 cases 
SLNs were processed only as routine axillary lymph nodes. First, during the evaluation of the 
95 cases, a total of 147 sentinel lymph nodes were examined (an average of 1.5 lymph nodes 
per patient, range 1–5). Metastasis was not confirmed in SLNs processed with serial 
sectioning. In 11 cases, additional axillary lymph nodes were removed besides successful 
SLNB; metastasis was not confirmed in the removed axillary lymph nodes. These lymph 
nodes were processed with routine HE staining. In the other 13 cases (8 cases of ALND – 
processed with routine HE method + 5 cases of successful SLNB, but processed with routine 
HE method), metastasis was not confirmed either.  
26 of the 112 (26/112, 23.2%) patients required a second complementary operation: 
mastectomy in 12 cases, and reexcision in 14. Residual tumor was verified in 10 patients 
treated with mastectomy and 7 patients treated with reexcision. One patient treated with 
reexcision underwent mastectomy because of positive resection margin during the reexcision 
(Table 11). 
Complementary 
surgery 
Number 
of cases 
% 
Residual 
tumor (N) 
% 
Reexcision 14 12.5 7 6.3 
Mastectomy 12 10.7 10 8.9 
Table 11. Reoperations and results in case of patients with in situ breast cancer 
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Discussion 
The extensive use of mammography has resulted in the increased detection rate of early-
stage non-palpable malignant breast tumors. Both the GWL and the ROLL methods are 
widely applied in surgical therapy to reveal and to remove non-palpable breast tumors. The 
GWL method is the more widespread technique in use today despite some well-known 
disadvantages: [1] radiologically, the guidewire placement is a difficult procedure to carry 
out; spontaneous wire displacement, and inability to reposition can occur as well. [2] The 
procedure is traumatic, causing discomfort and pain to the patient; furthermore, the wire must 
remain in place until the operation. [3] The surgical excision of a wire-located lesion with 
clear margins is a technically difficult procedure. There is obvious interference with the 
incision line and the surgical approach, and the wire can be accidentally transected as well. 
The ROLL method was developed to overcome some of the disadvantages of the GWL 
technique. Its reported advantages include precise localization, accurate surgical removal, 
higher rate of clear margins, reduced size of the excised specimen, better concentricity of the 
lesion, less patient discomfort, shorter operating time, and reduced numbers of reoperations, 
with an accompanying reduction in costs. Despite the fact that the ROLL technique has been 
available for more than 10 years now, only a few studies have been published about it. The 
GWL and the ROLL techniques have been compared only in 11 clinical studies and subjects 
were randomized only in 4 studies (Table 12).
33,34,35,36,37,38,39,40,41,42,43
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Authors Year Patients, N 
Involved surgical 
margins % p value 
  ROLL GWL ROLL GWL  
Luini et al. 
33
 1999 30 30 0 0 NS 
Rampaul et al.®34 2004 48 47 NA NA NA 
Ronka et al. 
35
 2004 64 14 8 28.6 0.03 
Gallegos-Hernandez et al.
36
 2004 65 67 16.9 35.8 0.014 
Zgajnar et al.
37
 2005 51 92 29.4 55.2 0.005 
Nadeem et al. 
38
 2005 65 65 17 43 0.001 
Thind et al. 
39
 2005 70 70 16.2 40 0.002 
Strnad et al. 
40
 2006 21 12 NA NA NA 
Moreno et al.® 41 2008 61 59 10 12.5 NS 
Medina-Franco et al.® 42 2008 50 50 11.1 37.5 0.04 
Martinez et al. ® 43 2009 66 68 10.6 17.6 NS 
Present study 2012 321 69 14.6 23.2 NS 
Table 12. Comparison of international results on the complete excision rates with the 
ROLL and the GWL techniques (®-randomized, NA-not available,  
NS-not significant) 
Altogether 6 trials have described a significant difference regarding the clear resection 
margins in favor of the ROLL technique.
35,36,37,38,39,42
 3 studies have found that the 
volume/weight ratio of the excised specimen was lower in the ROLL group than in the GWL 
group.
35,37,41
 Several studies have confirmed the well-known advantages of the ROLL method, 
such as better cosmetic results 
38,39,41, less perioperative pain 34,41 and shorter localization 
time.
38,39,42
 The newest systematic review demonstrated that radioguided localization 
techniques (including ROLL and radioguided seed localization (RSL) methods) produce 
lower positive resection margin rates and consequently fewer reoperations. However, this 
review was limited by its small size and the quality of the randomized controlled trials.
44
 A 
recently published multicenter, randomized, controlled trial compared the RSL method to a 
standard GWL technique in the detection of non-palpable invasive and in situ breast 
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carcinomas.
45
 In contrast to other trials, the positive resection margins and the reoperation 
rates were similar in both techniques, but the operating time was shorter when using RSL. It is 
important to know that in the RSL method, a radio-opaque titanium seed containing an 
125
I-
isotope was used, therefore it is not exactly equivalent to the classic ROLL method.  
In the present study, we did not find any significant differences between the two 
compared methods in respect of the proportion of the average volume of the removed 
specimen, the proportion of positive surgical margins, the incidence of residual tumors 
(removed during a second operation), or the frequency of postoperative wound infections. 
Preoperative localization time was significantly lower in the ROLL group, but there was no 
significant difference in the duration of surgical excision. Nevertheless, our surgeons found 
the ROLL method technically easier. International study results suggest a higher rate of 
successful primary tumor excision (clear resection margins) with the use of the ROLL method 
(Table 12). Higher clear resection margin rates were found in the ROLL group in our study as 
well, but the difference was not significant statistically (85.4% vs. 76.8%). Although the 
average removed specimen volume and the pathological tumor size were higher in the ROLL 
group than in the GWL group, they were not significantly different. We did not find any 
significant difference in the ratio of the tumor size and the removed specimen volume. This 
indicates that a relatively smaller specimen can be removed safely using the ROLL method 
for the same tumor size. Another important advantage of the ROLL technique is that it allows 
concomitant removal of the invasive breast lesion and the SLN(s). Furthermore, our 
investigation revealed that by applying the ROLL method, the involved surgical margin was 
influenced by the tumor size, by the existence of a multifocal tumor, and by the presence of an 
extensive in situ breast cancer around the invasive tumor. In case of the GWL technique, the 
frequency of positive resection margins was influenced by the tumor size, by the presence of 
an extensive in situ breast cancer around the invasive tumor and by a lower specimen volume. 
It is important to emphasize that the size of the tumor was bigger and the specimen volume 
was lower in the GWL group with positive resection margins. Therefore, the ratio of the 
tumor size and the removed specimen volume are more indicative factors of the occurrence of 
a positive resection margin than just the size of the tumor or the removed specimen volume 
itself alone. Several studies have proved that the frequency of a positive resection margin is 
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significantly increased by the size of the tumor
46.47
, by the presence of an extensive in situ 
tumor around the invasive tumor
46,48
, by the presence of multifocal tumors
46,49 
and by the 
volume of the removed specimen.
46,49
 Considering these facts, it is noteworthy that the most 
important predictive factor of a local tumor recurrence in breast-conserving surgery is a 
positive resection margin.
50,51,52
 If the final surgical margins are negative, the 5-year risk of 
local failure is 2–7%, whereas with positive margins, this risk can rise up to 16% or even 
higher
53,54,55,56
. In addition to the surgical margin status, factors such as young age, large 
tumor size, adjuvant chemotherapy and hormonal therapy, and positive ALNs are all 
significant independent predictors of locoregional recurrence.
57
 
International results show that both the GWL and the ROLL methods are suitable for the 
localization and subsequent removal of non-palpable breast tumors. We have come to the 
same conclusion in our study. However, the ROLL method has more advantages, such as 
shorter localization time, more accurate surgical excisions and less discomfort to the patient. 
We recommend that the ROLL method should be used for the localization of non-palpable 
breast tumors if preoperative examinations prove the presence of an invasive breast cancer 
and SLNB is also to be considered. We would recommend the use of the GWL technique in 
cases with extensive microcalcifications and when SLNB is not going to be performed (pure 
DCIS, radial scar, etc.).  
Besides BCSs, SLNB, which is an accepted indicator of the axillary lymph node status 
has come to the front. In accordance with previous clinical practice, complementary ALND 
was routinely performed in case of metastatic SLN.
12,13,14
 However, several studies have 
highlighted that it was unnecessary in approximately 2/3 of the cases as additional metastasis 
was not detected in the removed lymph nodes.
15,16
 Increased risk for the occurrence of ALND 
related complications, as well as the additional cost of the surgery and the treatment of 
potential complications indicate the development of methods that may predict the probability 
of additional axillary metastasis. This method may help in preventing or at least reducing the 
number of ALNDs performed unnecessarily in case of SLN positivity. Eight NSLN 
metastasis predictive models are used in the clinical practice currently.
58,59,60,61,62,63,64,65 
The 
prospective study of Van Zee and colleagues (2003) studied the patients of the Memorial 
Sloan-Kettering Cancer Center (MSKCC) in New York. 1075 patients with primary invasive 
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breast tumor and SLN metastasis were studied in 6 years. All patients had complementary 
ALND surgery. Multiparametric logistic regression was used to perform a predictive 
nomogram to predict the NSLN metastasis. The nomogram is available online at 
www.mskcc.org/nomograms. From the studied factors, tumor size, presence of LVI, presence 
of multifocal tumor, method of detection of SLN metastasis (frozen section, routine HE, SS, 
IHC), and number of positive and negative SLNs correlated with the incidence of the NSLN 
metastasis. A drawback of the study is that the examination of the axillary lymph nodes was 
performed with routine HE method; in case of SS, this number would have been higher. Exact 
size of SLN metastasis was missing, however, the method of detection may correlate with 
this. The most important disadvantage of the study is that the model does not determine when 
ALND should be performed, it only predicts the probability of the metastasis.
58
 In a 
prospective study of Hwang and colleagues (2003), 131 patients of the MD Anderson Cancer 
Center, Texas were evaluated similarly. Their results showed that the tumor size, presence of 
LVI, the size of metastasis in the SLN increased the occurrence of NSLN metastasis, and the 
number of removed SLNs was a significant negative predictor for NSLN metastasis. The 
predictive nomogram is available online as well 
(http://www3.mdanderson.org/app/medcalc/bc_nomogram2/index.cfm?pagename=nsln). The 
developed score system includes a positive and negative predictive value besides sensitivity 
and specificity. The disadvantage of the model is that sensitivity was decreased in case of 
higher values, and specificity was reduced in case of lower scores.
59
 Degnim and colleagues 
(2005) studied 574 patients having invasive breast tumor with clinically negative axillary 
status in the Mayo Clinic and University of Michigan were assessed under similar 
circumstances, and age, tumor size, size of the SLN metastasis, ER positivity, extracaspular 
spreading, number of positive and negative SLNs correlated statistically significantly with the 
NSLN metastasis. The method is simpler and uses more easily available clinicopathological 
factors compared with the MSKCC nomogram.
60 
Barranger and workgroup (2005) enrolled 
71 patients with SLN metastasis in their analysis similarly, they evaluated the tumor size, type 
of the SLN metastasis (presence of macrometastasis), and the ratio of removed positive and 
negative SLNs in the final NSLN metastasis predictive model.
61 
Chapgar and colleagues 
(2006) included 1253 patients in their multicenter, prospective database, and they found that 
the tumor size (T), and the number and ratio of positive SLNs influenced the presence of 
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additional NSLN metastasis. A novel factor was that they studied the experience of the 
surgeon and differences among various regions as well. The drawback of the study was that 
ER, PR, HER2 status, grade, LVI, and size of SLN metastasis were not examined.
62 
Khort and 
colleagues published a prospective multicenter (16 institutions) study in 2008 examining 285 
patients under similar circumstances and found that the tumor size, presence of LVI, and the 
size of the SLN metastasis influenced metastasis formation in NSLNs. This model was the 
first emphasizing synergistic interactions between factors (LVI and size of SLN metastasis, as 
well as between tumor size and size of SLN metastasis). The predictive model (Stanford 
nomogram) is available online as well (http://www3-hrpdcc.stanford,edu/nsln-calculator).
63 
In 
2009, Houvenaeghel studied 909 cases in a retrospective multicenter (16 institutions) study 
with similar criteria, however only cases of SLN micrometastasis were evaluated. The study 
showed that the tumor size, detection method of the SLN micrometastasis, presence of LVI, 
and the histological type of the tumor influenced the development of NSLN metastasis. 
Omission of ALND could be recommended only in case of minimal risk for a low probability 
of NSLN metastasis (<10%).
64
 Coufal and colleagues (2009) enrolled 330 patients in a similar 
way with similar criteria to develop a predictive model which was validated in a population of 
383 patients operated on for having breast tumor in the Department of Surgery in the 
Kecskemét Hospital and who met the criteria. The final predictive model included tumor size, 
histological type, multifocality, presence of LVI, size of SLN metastasis, extranodal 
spreading, and the ratio of positive SLNs.
65
 The most commonly used nomograms and 
evaluated and significant factors are summarized in Table 13.  
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   Nomograms 
 
Variables MSKCC58  MDA59 Mayo60 Tennon score61 Luisville62 Stanford63 French micrometastasis64 Masaryk65 
Age No No Yes No No No No No 
Tumor size Yes Yes Yes Yes Yes Yes Yes Yes 
     Categorical No Yes Yes Yes Yes Yes Yes Yes 
     Continuous Yes No No No No Yes No No 
Tumor type Yes No No No No No Yes Yes 
Nuclear grade Yes No No No No No No No 
LVI Yes Yes No No No Yes Yes Yes 
ER status Yes No Yes No No No No No 
Multifocality Yes No No No No No No Yes 
No of pos.SLNs Yes No Yes No Yes No No No 
No of neg.SLNs Yes No Yes No No No No No 
No of SLNs No Yes No No No No No No 
Rate of pos. SLNs No No No Yes Yes No No Yes 
Detection of SLN met. Yes No No No No No Yes No 
Size of SLN met. No Yes Yes Yes No Yes No Yes 
    Categorical No Yes Yes Yes No Yes No Yes 
    Continuous No No No No No No No No 
Extracapsular spreading No No Yes No No No No Yes 
Table 13. Variables included in the different predictive models tested 
. Evaluation of the nomograms revealed that these models are not better predictive 
systems in predicting NSLN metastasis in our patient population either. Based on our studies, 
the most reliable methods are the Chapgar (AUC: 0.766) and MSKCC nomograms (AUC: 
0.726) (Figure 6-7). 
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MSKCC nomogram French micrometastasis nomogram 
 
 
 
 
Tenon score nomogram Luisville prediction nomogram 
Figure 6. Evaluation of the sensitivity and specificity of predictive nomograms in our patients 1. 
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Mayo nomogram Masaryck nomogram 
 
 
 
 
Stanford nomogram MDA nomogram 
Figure 7. Evaluation of the sensitivity and specificity of predictive nomograms in our patients 2. 
Cserni and colleagues (2012) studied and compared the above described 8 nomograms 
and their predictive values in their multicenter study using the clinical data of the University 
of Szeged as well. 200 patients having invasive breast tumor and positive SLN and in case of 
whom ALND was performed were enrolled in the study from all centers (a total of 1000 
patients). A low risk value for NSLN metastasis was assigned to the nomograms, and its 
predictive value was studied and compared. Note that clinicopathological examination of the 
SLN, or even the processing of the primary tumor may be different, therefore inter-
institutional difference was detected, which is important in identifying the low risk group as 
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well. Therefore, validation of the selected method is recommended in an institutional level 
and the most appropriate one should be used.
66
 In another study of Cserni and colleagues 
(2012), predictive nomograms were used to identify patients with high risk for NSLN 
metastasis (>50%) who would benefit from ALND.
67
 1000 patients having invasive breast 
tumor and SLN metastasis as well as ALND were enrolled (200 from the University of 
Szeged) in the study. Patients with micrometastatic SLNs were tested separately. They results 
showed that identification of high risk patients is much worse than that of patients with low 
risk for NSLN metastasis. There were inter-institutional differences of nomograms as well 
regarding positive predictive values. Therefore, the nomograms should be validated and 
selected that is most suitable for the institution. In case of SLN micrometastasis, the risk of 
additional NSLN metastasis is low irrespective of the fact that the patient is in the high or low 
risk group, so in such cases, ALND is not recommended. The recommendation of the 2011 St 
Gallen Consensus conference is similar as well.
68
 Meretoja and colleagues performed a new 
retrospective study with 200 cases from each 5 centers (including the University of Szeged) 
examining the same factors. Their aim was to prepare a predictive model for NSLN 
metastasis. After this, an internal (500 cases) and an external (1068 cases) validation was 
performed. Logistic regression was used with the data of the original 1000 patients and the 
probability of NSLN metastasis was determined with a mathematical model including LVI, 
mutifocality, HER2 status, number of negative and positive SLNs, tumor size, size of the SLN 
metastasis, and extracapsular spreading as significant variables. (The model is available 
online at http://www.hus.fi/breastsurgery/prediktivemodell.)
69
 The gold standard in case of 
SLN positivity is performing ALND, the role of ALND has recently become controversial in 
selected cases. One of the most important studies examining this was the Z0011 trial 
performed by an American surgeon-oncologist team and was described by Guliano and 
colleagues in 2010 including patients with invasive breast tumor with T1-2, N0, M0 clinical 
stage in case of whom SLNB was performed in addition to the removal of the tumor, and 
macro-, or micrometastasis was found in the SLN. Pregnant women and patients receiving 
neoadjuvant therapy were excluded from the study. Patients were randomized into two 
groups, complementary ALND was performed in one group, and there were no additional 
surgical interventions or special complementary treatments in the other group. Finally, 388 
patients having ALND were compared with 425 patients who did not have ALND. The 
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average duration of the follow-up was 6.3 years. The ratio of locoregional recurrence was 
3.4% of the total patient population. There were no significant differences in local recurrence 
or regional recurrence (ipsilateral axilla), or the average time until the recurrence between the 
two groups. Members of both groups received systemic adjuvant oncological therapy 
(hormone therapy and chemotherapy) in similar ratio. Type of chemotherapy was similar as 
well. The ratio of locoregional recurrence was not significantly different in case of patients 
receiving systemic adjuvant oncology treatment and patients not receiving such treatment. 
Consequently, completing ALND was not beneficial in locoregional control even if tumor-
containing lymph nodes were removed.
70
 The effect of ALND on survival was also studied in 
this patient population. 5-year survival was similar between the two groups. 5-year disease-
free survival was not significantly different either. Incidence of surgical complications 
(paresthesia, wound infection, seroma, lymphedema) increased in the ALND group. 
71
  
In our patient population, 271 patients were confirmed to have SLN metastasis, 205 
ALND procedures were performed, and 70 patients in 205 had additional confirmed 
metastasis. Based on our study results it can be concluded that in our patient population, 
additional NSLN metastasis was influenced by the age of patients, the tumor size and the type 
(size) of the SLN metastasis among the studied prognostic factors in case of SLN metastasis. 
A precise predictive nomogram to predict NSLN metastasis could not be created. The 
predictive value of the nomogram is better when the size of the SLN metastasis is known 
compared to when only the type of the SLN metastasis is known. The predictive nomogram is 
relatively more precise in identifying NSLN metastasis in patients with lower risk for NSLN 
metastasis however, it is still not suitable for precise prognosis. 
An increasing number of cases of malignant or malignant-suspicious non-palpable 
breast disease have been recognized since the introduction of mammographic screening. The 
same holds for the incidence of DCIS among early detected breast cancers.
19,20 
DCIS is a non-
invasive breast cancer, and is therefore not expected to give metastases. The conference 
organized in the USA in 1999 accepted the suggestion that it was unnecessary to perform 
ALND if the diagnosis was pure DCIS.
20
 However, some authors consider that SLNB in pure 
DCIS is controversial, even though this might appear unnecessary. A number of studies have 
been published on this issue. It was reported by the H. Lee Moffitt Cancer Center in 2000 that 
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5 of 87 patients (5/87, 5.7%) had metastases in the SLNs.
29
 These results led to their proposal 
to perform SLN biopsy in patients with pure DCIS. In 2003, the European Institute of 
Oncology Team reported metastases in the SLNs in 7 of 223 patients with pure DCIS (7/223, 
3.1%). 6 of the 7 patients underwent ALND, but other metastases were not detected.
27
 They 
published new results in 2005, with an SLN positivity rate lower than 2 years previously 
(9/508, 1.8%)
72
. Results from Padova indicated that only 1 of 102 patients (1/102, 1%) had 
metastasis in the SLNs and this was micrometastasis.
24
 Similar findings were published by the 
Cleveland Clinic Breast Center (3/134, 2%), but it is important that only 41 of those patients 
underwent SLNB, and the other 93 axillary sampling. 1 of the 41 patients (1/41, 2%) 
exhibited SLN positivity.
26 
The New Orleans Ochsner Clinic Foundation investigated 44 
patients with pure DCIS and found no metastasis in the SLNs.
73
 Other studies evaluated the 
incidence of SLN metastasis in DCIS and DCISM cases as well. These results can be seen in 
Table 14 as well.
21,28,30,74
 Thus, the rate of SLN positivity in these literature reports ranged 
from 0% to 12% in patients with pure DCIS and from 10 to 16% in those with DCISM (Table 
14).  
Reference N SLN positivity % 
Intra, M
27 
(DCIS)
 
223 7  3.1 
Pendas, S
29
 (DCIS) 87 5   5.7 
Klauber-De More,N
22 
(DCIS) 76 9 11.8 
Veronesi, P.
72 
(DCIS) 508 9    1.8 
Zavagno, G
24 
(DCIS) 102 1 1 
Kelly, TA
26 
(DCIS) 134 3     2.2 
Farkas, EA
73 
(DCIS) 44 0 0 
Wilkie C
30 
(DCIS) 552 27 5 
Intra
28 
(DCISM) 41 4 9.7 
Klauber-De More, N21 (DCISM) 31 3 10 
Wilkie C
30 
(DCISM) 51 7 13.7 
Camp R
74 
(DCIS + DCISM) 43  7 16.3 
Table 14. Literature results on SLN positivity rate in DCIS and DCISM patients 
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How can a tumor be defined as non-invasive, which gives metastasis to the lymph 
nodes? One explanation may be an inappropriate histological diagnosis. A microinvasive or 
invasive focus that can give metastasis cannot be detected in the specimen besides the DCIS. 
An accurate preoperative histological diagnosis is important if the patient is suspected of 
having DCIS breast cancer. The main preoperative histological method in our institute is 
FNAC, but this is not appropriate for the identification of DCIS preoperatively. FNAC was 
not informative (C1) in 37.3% of our patients in whom in situ breast cancer was detected and 
malignant cells (C5) were observed in only 26.7%, but the presence of DCIS could not be 
diagnosed. CNB is a more effective method than FNAC, but FNAC is the primary 
preoperative histological method in Hungary because of its cheapness.
75
 The literature 
indicates that CNB is not a reliable method either. A group from Tampa investigated 613 
DCIS patients: 290 (290/613, 47%) underwent preoperative CNB, 301 (301/613, 49%) had 
excisional biopsy and 9 (9/613, 2%) had FNAC. DCISM was detected in 62 patients. 20 of 
the 62 patients (20/62, 32%) underwent CNB, 40 (40/62, 65%) had excisional biopsy and 2 
(2/62, 3%) had FNAC. The final histological examination indicated that 15 of the 301 patients 
(15/301, 5%) with excisional biopsy had a proven invasive component besides the DCIS. The 
rate in CNB was higher (38/290, 13%). The rate in preoperative DCISM patients was higher: 
4 of the 40 (4/40, 10%) patients with a preoperative excisional biopsy and 6 of the 20 (6/20, 
30%) patients with a preoperative CNB had a proven invasive component in the sample.
30
 The 
reliability of CNB has likewise been investigated (Table 15). 
76,77,78
 These results 
demonstrated that CNB is not a perfect method with which to detect pure DCIS, because there 
can be an invasive component in the specimen (range 13-38%) besides the DCIS. 
Reference N N (wrong) % 
Wilkie C 
30
 290 38 13 
Kurniawan E 
76
 375 65 17.3 
Mittendorf MEA
77
  30 6 20 
Goyal A 
78
 587 220 38 
Table 15. Literature results on CNB reliability in DCIS patients 
Another important circumstance is the pathological examination of the SLNs. In our 
institute SLNs have been examined by HE serial sectioning at 250 m intervals and by IHC, 
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which is an effective method to verify micrometastasis (<2 mm) and ITC metastasis (<0.2 
mm) in the SLNs. The more detailed the preparation of the SLN, the greater the chance that 
metastasis will be found in it, and this too can cause different results concerning SLN 
positivity. A study from the Bethesda National Cancer Institute reported that the rate of SLN 
positivity detected by IHC in the range of 2-13% when the diagnosis was high-grade DCIS, 
and in the range of 8-20% when it was DCISM; 
79
 this was in contrast with the earlier ALND 
method, which revealed an average 2% positivity in the lymph nodes. The studies from the 
New York Columbia University and the Netherlands Cancer Institute furnished similar 
results. These studies investigated patients with a long–term follow-up (127 months) and 
found that, as compared with SLN negative patients, the survival time was not influenced by 
the presence of micrometastasis or ITC metastasis in the SLNs if this was detected only by 
IHC. Accordingly, these patients did not require other surgical treatment.
80
 It is important that 
patients with SLN positivity underwent ALND, and other metastases were not detected in the 
removed lymph nodes. In the majority of the SLN positive patients, only micrometastasis was 
detected. These results suggest that axillary block dissection is unnecessary. 
The literature and our own experience lead us not to recommend SLNB in all patients 
with DCIS. SLNB can be necessary in certain circumstances: If the preoperative histological 
diagnosis indicates a microinvasive focus in the sample, then SLNB is necessary 
simultaneously. We suggest that, if the final histological examination indicates an invasive or 
microinvasive focus, SLNB should be recommended as a second step. It is further suggested 
that, if the indication is an extended DCIS tumor, and the patients must be treated with 
mastectomy, then simultaneous SLNB is recommended, because an invasive or microinvasive 
focus cannot be detected in the tumor and SLNB is impossible after mastectomy. If the 
histological examination detects micrometastasis or ITC metastasis in the SLNs, no other 
operation is necessary. A correct preoperative diagnosis is very important. If the preoperative 
histological diagnosis is based only on FNAC (together with mammography and breast 
ultrasound), we have two choices. We can perform an SLNB, which does not cause 
significant morbidity, but is expensive, or we can base the necessity of SLNB on the final 
histological diagnosis, and perform it as a second step. 
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Summary and new results 
 Our results proved that both the GWL and the ROLL methods are suitable for the 
localization and subsequent removal of non-palpable breast tumors. The most important 
advantage of the ROLL is the shorter localization time. 
 
 We recommend that the ROLL method should be used for the localization of non-
palpable breast tumors if preoperative examinations prove the presence of an invasive 
breast cancer and SLNB is also to be considered. We would recommend the use of the 
GWL technique in cases with extensive microcalcifications and when SLNB is not 
going to be performed (pure DCIS, radial scar, etc.). 
 
 The incidence of NSLN metastasis of invasive breast tumors was influenced 
significantly only by the age of the patients, the size of the tumor, and the size (type) of 
the metastasis in the SLN in case of SLN positivity. 
 
 The studied clinical and the histological characteristics cannot be used to create a 
predictive nomogram that would predict the incidence of NSLN metastasis with good 
specificity and sensitivity. However, the developed predictive nomograms predict the 
incidence of NSLN metastasis more precisely in case of lower predictive risk; it is not 
suitable to exactly predict the incidence in this range either, so the probability of NSLN 
metastasis cannot be precisely predicated with the currently studied factors. 
 
 Evaluation of the eight international NSLN predictive nomograms in our patients 
showed that these nomograms are not superior either and therefore cannot be used to 
predict NSLN metastasis reliably. 
 
 Our studies confirm that in case of pure DCIS, there were no metastases in the SLNs, 
SLNB may be avoided in such cases. In case of extensive in situ breast cancers, if the 
primary surgery is mastectomy, SLNB should be performed simultaneously. 
 
 If the final histological examination indicates an invasive or microinvasive focus, 
SLNB should be recommended as a second step. 
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